FDA Approves Hemophilia B Second Gene Therapy.

Published Date: 29 Apr 2024

Standard prophylactic factor IX was found to be noninferior to one dose of fidanacogene elaparvovec.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

WHO releases new R&D landscape analyses highlighting gaps and inequities in cancer research

2.

Pirtobrutinib Delays Progression in CLL Already Treated With a BTK Inhibitor

3.

Hypnotherapy may offer real benefits for cancer patient care

4.

Prostate cancer mortality is significantly reduced when docetaxel is used.

5.

Mezigdomide Combinations Show Promise in Multiple Myeloma


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot